FULCRUM THERAPEUTICS, INC. Operating Cash Flow
FULCRUM THERAPEUTICS, INC. (FULC) reported Operating Cash Flow of -$34.79 million for the 6-month period ending 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-09-02
- FULCRUM THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$16.04M.
- FULCRUM THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$18.75M.
- FULCRUM THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$16.80M.
- FULCRUM THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$14.19M.
- FULCRUM THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$90.97M.
- FULCRUM THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$97.05M.
- FULCRUM THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2021 was -$78.48M.
- FULCRUM THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2020 was -$53.66M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$16.04M derived: S-4 6 month − 10-Q 3 month · filed 2026-09-02 | -$34.79M S-4 · filed 2026-09-02 | -$51.59M derived: sum of 3 quarters · filed 2026-09-02 | -$65.78M derived: sum of 4 quarters · filed 2026-09-02 |
| 2026-03-31 | -$18.75M 10-Q · filed 2026-04-27 | -$35.55M derived: sum of 2 quarters · filed 2026-09-02 | -$49.74M derived: sum of 3 quarters · filed 2026-09-02 | -$63.56M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-12-31 | -$16.80M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | -$30.99M derived: sum of 2 quarters · filed 2026-09-02 | -$44.81M derived: sum of 3 quarters · filed 2026-09-02 | -$60.06M S-4 · filed 2026-09-02 |
| 2025-09-30 | -$14.19M derived: 10-Q 9 month − S-4 6 month · filed 2025-10-29 | -$28.01M derived: sum of 2 quarters · filed 2026-09-02 | -$43.27M 10-Q · filed 2025-10-29 | -$60.03M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-06-30 | -$13.82M derived: S-4 6 month − 10-Q 3 month · filed 2026-09-02 | -$29.08M S-4 · filed 2026-09-02 | -$45.84M derived: sum of 3 quarters · filed 2026-09-02 | -$64.91M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-03-31 | -$15.26M 10-Q · filed 2026-04-27 | -$32.02M derived: sum of 2 quarters · filed 2026-09-02 | -$51.09M derived: sum of 3 quarters · filed 2026-09-02 | $7.81M derived: sum of 4 quarters · filed 2026-09-02 |
| 2024-12-31 | -$16.76M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | -$35.83M derived: sum of 2 quarters · filed 2026-09-02 | $23.07M derived: sum of 3 quarters · filed 2026-09-02 | -$2.22M S-4 · filed 2026-09-02 |
| 2024-09-30 | -$19.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $39.83M derived: sum of 2 quarters · filed 2025-10-29 | $14.54M 10-Q · filed 2025-10-29 | -$8.62M derived: sum of 4 quarters · filed 2025-10-29 |
| 2024-06-30 | $58.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $33.62M 10-Q · filed 2025-07-29 | $10.46M derived: sum of 3 quarters · filed 2025-07-29 | -$12.45M derived: sum of 4 quarters · filed 2025-07-29 |
| 2024-03-31 | -$25.28M 10-Q · filed 2025-05-01 | -$48.44M derived: sum of 2 quarters · filed 2025-05-01 | -$71.35M derived: sum of 3 quarters · filed 2025-05-01 | -$92.13M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | -$23.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$46.06M derived: sum of 2 quarters · filed 2025-02-25 | -$66.85M derived: sum of 3 quarters · filed 2025-02-25 | -$90.97M 10-K · filed 2025-02-25 |
| 2023-09-30 | -$22.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$43.69M derived: sum of 2 quarters · filed 2024-11-13 | -$67.81M 10-Q · filed 2024-11-13 | -$87.50M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$20.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | -$44.90M 10-Q · filed 2024-07-31 | -$64.60M derived: sum of 3 quarters · filed 2024-07-31 | -$92.48M derived: sum of 4 quarters · filed 2024-07-31 |
| 2023-03-31 | -$24.12M 10-Q · filed 2024-05-13 | -$43.81M derived: sum of 2 quarters · filed 2024-05-13 | -$71.69M derived: sum of 3 quarters · filed 2024-05-13 | -$99.06M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$19.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$47.58M derived: sum of 2 quarters · filed 2024-02-27 | -$74.94M derived: sum of 3 quarters · filed 2024-02-27 | -$97.05M 10-K · filed 2024-02-27 |
| 2022-09-30 | -$27.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$55.25M derived: sum of 2 quarters · filed 2023-11-07 | -$77.35M 10-Q · filed 2023-11-07 | -$99.21M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$27.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$49.47M 10-Q · filed 2023-08-03 | -$71.33M derived: sum of 3 quarters · filed 2023-08-03 | -$93.90M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$22.11M 10-Q · filed 2023-05-15 | -$43.96M derived: sum of 2 quarters · filed 2023-06-26 | -$66.54M derived: sum of 3 quarters · filed 2023-06-26 | -$84.36M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-12-31 | -$21.86M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | -$44.43M derived: sum of 2 quarters · filed 2023-06-26 | -$62.25M derived: sum of 3 quarters · filed 2023-06-26 | -$78.48M 10-K/A · filed 2023-06-26 |
| 2021-09-30 | -$22.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$40.39M derived: sum of 2 quarters · filed 2022-11-08 | -$56.62M 10-Q · filed 2022-11-08 | -$76.45M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-06-30 | -$17.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$34.05M 10-Q · filed 2022-08-11 | -$53.87M derived: sum of 3 quarters · filed 2023-06-26 | -$58.38M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-03-31 | -$16.23M 10-Q · filed 2022-05-09 | -$36.05M derived: sum of 2 quarters · filed 2023-06-26 | -$40.56M derived: sum of 3 quarters · filed 2023-06-26 | -$54.68M derived: sum of 4 quarters · filed 2023-06-26 |
| 2020-12-31 | -$19.83M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | -$24.33M derived: sum of 2 quarters · filed 2023-06-26 | -$38.45M derived: sum of 3 quarters · filed 2023-06-26 | -$53.66M 10-K/A · filed 2023-06-26 |
| 2020-09-30 | -$4.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$18.63M derived: sum of 2 quarters · filed 2021-11-04 | -$33.83M 10-Q · filed 2021-11-04 | -$38.32M derived: sum of 4 quarters · filed 2023-06-23 |
| 2020-06-30 | -$14.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$29.32M 10-Q · filed 2021-08-10 | -$33.82M derived: sum of 3 quarters · filed 2023-06-23 | -$46.84M derived: sum of 4 quarters · filed 2023-06-23 |
| 2020-03-31 | -$15.20M 10-Q · filed 2021-05-06 | -$19.70M derived: sum of 2 quarters · filed 2023-06-23 | -$32.72M derived: sum of 3 quarters · filed 2023-06-23 | -$44.79M derived: sum of 4 quarters · filed 2023-06-23 |
| 2019-12-31 | -$4.50M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-23 | -$17.51M derived: sum of 2 quarters · filed 2023-06-23 | -$29.59M derived: sum of 3 quarters · filed 2023-06-23 | -$39.48M 10-K/A · filed 2023-06-23 |
| 2019-09-30 | -$13.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$25.09M derived: sum of 2 quarters · filed 2020-11-10 | -$34.99M 10-Q · filed 2020-11-10 | -$41.39M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | -$12.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | -$21.97M 10-Q · filed 2020-08-11 | -$28.37M derived: sum of 3 quarters · filed 2020-08-11 | -$32.49M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | -$9.90M 10-Q · filed 2020-05-13 | -$16.30M derived: sum of 2 quarters · filed 2020-05-13 | -$20.42M derived: sum of 3 quarters · filed 2020-05-13 | |
| 2018-12-31 | -$6.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | -$10.52M derived: sum of 2 quarters · filed 2020-03-05 | -$22.56M 10-K · filed 2020-03-05 | |
| 2018-09-30 | -$4.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$16.16M 10-Q · filed 2019-11-14 | ||
| 2018-06-30 | -$12.04M 10-Q · filed 2019-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |